SLC5A2 and atherosclerosis: These changes promote a reduction in intravascular volume, arterial blood pressure, cardiac preload, and cardiac afterload.2,24 Among subjects with the triad of type 2 diabetes, chronic kidney disease, and no known preexisting ASCVD, those who had the highest glucosuria while treated with the SGLT2 inhibitor canagliflozin, also had the strongest protection against multiple cardiorenal outcomes.22